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Introduction
Voriconazole (VRCZ) is a triazole antifungal developed
for the treatment of fungal infectious disease and is avail-
able for both oral and intravenous administration. It has
potent activity against a broad spectrum of clinically sig-
niﬁcant pathogens, including Aspergillus, Candida, Cryp-
tococcus, Fusarium, and Scedosporium [1]. VRCZ has a
nonlinear pharmacokinetic proﬁle with wide inter- and
intraindividual variability [2]. This variability is caused by
many factors, such as sex, age, race, genotypic variation,
liver dysfunction, and the presence of food. Another
important factor inﬂuencing the VRCZ pharmacokinetic
proﬁle is drug–drug interactions with CYP450 inhibitors as
well as inducers. Genotypic variation in the metabolizing
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enzyme CYP2C19 is one of the major determinants of the
VRCZ blood level. The frequency of poor metabolizers
(PM), with defective or diminished metabolic capacity, is
higher among Japanese patients. Variability in the plasma
concentrations, arising from these previously mentioned
aspects, may lead to variability in efﬁcacy or toxicity.
Determining the plasma concentration is indicated in some
situations to guide dosing and to individualize and improve
the treatment options, resulting in a better therapeutic
outcome or fewer side effects.
In this guideline, we review the factors that inﬂuence the
VRCZ pharmacokinetic proﬁle, the data supporting expo-
sure–effect and exposure–toxicity relationships that make
broad recommendations for therapeutic drug monitoring
difﬁcult for VRCZ, and provide indications for which
therapeutic drug monitoring is reasonable based on cur-
rently available data (for example, in children). We also
outline ways in which the existing problems can be solved.
Methods
The practice guidelines for therapeutic drug monitoring
(TDM) of VRCZ were reviewed by a practice guideline
committee, consisting of 18 experts in the ﬁeld of TDM
(Expert Panel) convened from the Japanese Society of
Chemotherapy (JSC) and the Japanese Society of Thera-
peutic Drug Monitoring (JSTDM). The Expert Panel
reviewed papers published since 2000 and additionally
analyzed data before 1999, if necessary. Computerized
PUBMED searches of the English-language literature and
Igaku-Chuo-Zasshi searches of the Japanese-language lit-
erature were performed using the terms ‘‘voriconazole’’
and ‘‘therapeutic drug monitoring’’ and focused mainly on
human studies; however, animal studies and in vitro data
were included if necessary. The committee speciﬁcally
looked for existing randomized clinical trials and existing
meta-analysis using a general database (i.e., MEDLINE,
EMBASE), and the Cochrane Library (both The Cochrane
Database of Systematic Reviews and Database of Abstracts
of Reviews of Effectiveness); however, few randomized
clinical trials and meta-analyses were available and many
recommendations were developed from observational
studies or small case studies.
To evaluate evidence regarding TDM, the Expert Panel
followed the Canadian Task Force recommendations [3],
which included a systematic weighting of the quality of the
evidence and a graded recommendation according to the
Minds classiﬁcation (Table 1). The Expert Panel met in
person on 7 occasions and by E-mail via mailing lists on
533 occasions. The draft guidelines for the executive
summary were placed on the homepage of the JSC and
JSTDM. Feedback from external public comments was
obtained between April 9, 2012, and May 8, 2012. The
guidelines for the Japanese version were approved by the
JSC and JSTDM Board of Directors and were published in
the Japanese Journal of Chemotherapy in June 2012.
All the members of the practice guideline committee
complied with the JSC policy on conﬂicts of interest, which
requires the disclosure of any ﬁnancial or other interest that
Table 1 Grading system for ranking recommendations and evidence
level adopted in the guideline
Category,
grade
Deﬁnition
Strength of recommendation
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for
use
C1 Recommendation for use regardless of poor evidence
C2 Poor evidence to support a recommendation for use
D Good-to-moderate evidence to support a
recommendation against use
Quality of evidence
I Evidence from C1 properly randomized, controlled
trial
II Evidence from C1 well-designed clinical trial, without
randomization from cohort or case-controlled
analytical studies, multiple time-series, or dramatic
results from uncontrolled experiments.
III Evidence from opinions of respected authorities, based
on clinical experience, descriptive studies, or reports
of expert committees
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might be construed as constituting an actual, potential, or
apparent conﬂict. Potential conﬂicts of interest are listed in
the Acknowledgments section. The committee will deter-
mine the need for revisions to the guidelines at 3-year
intervals.
Indications for TDM
Executive summary
(a) TDM for VRCZ is recommended for patients with a
poor response to therapy or suspected toxicity (B-II).
(b) TDM is considered in patients with a severe form
of mycosis, such as invasive Aspergillus infection
(C1-III).
(c) Visual adverse events may be associated with higher
plasma concentrations; however, many of these
events have been reported to be transient. TDM is
recommended especially for patients with sustained
visual disturbances (C1-III).
(d) VRCZ is extensively metabolized via cytochrome
P450 (CYP), and signiﬁcant interpatient variability in
VRCZ serum concentrations because of polymor-
phisms has been observed. TDM is recommended for
patients receiving drugs that are metabolized by
CYP450 (B-II).
(e) TDM is considered in patients undergoing hemato-
poietic stem cell transplantation (HSCT) who are
being treated with VRCZ as prophylaxis for deep-
seated mycosis (C1-III).
(f) TDM is considered for pediatric patients, as their
blood concentrations of VRCZ are highly variable and
ﬂuctuating (C1-III).
Literature review
Tan et al. [4] mentioned that routine monitoring of VRCZ
concentration to prevent elevated liver function and visual
disturbances was unlikely to add any clinical value. This
conclusion was based on the premise that regular moni-
toring of liver function while patients are receiving VRCZ
may be sufﬁcient and visual disturbances represent, in
general, a transient and mild effect that rarely necessitates
discontinuation of VRCZ therapy. In addition, lower and
upper target thresholds for VRCZ have been suggested, but
studies to date have not been appropriately designed or
powered to reveal any deﬁnitive association with its efﬁ-
cacy and toxicity [5]. Therefore, routine assessment of
TDM in VRCZ cannot be recommended as a mandatory
maneuver except in certain circumstances in this guideline.
The committee deﬁned particular indications for TDM in
several situations, such as lack of response to therapy or
evidence of toxicity, in which case the selective indication
for TDM is clinically useful.
VRCZ is associated with adverse events, including
visual disturbance and hepatic enzyme elevation with drug
overdosing. The steady-state blood concentration of VRCZ
has large interpersonal variability because it can be affec-
ted by several factors, including patient age, race, drug–
drug interactions, route of administration, cytochrome
P450 (CYP) polymorphism (mainly CYP2C19), and race
because of the polymorphism [5–12]. Several observational
studies have demonstrated that the blood trough level was
associated with adverse events [8, 10, 13–15].
Examination of weekly plasma concentration data from
patients in ten studies suggested that patients who reported
visual adverse events (VAE) had higher VRCZ plasma
concentrations [12]. Kakuda et al. [16] mentioned that
coadministration of etravirine with VRCZ resulted in higher
etravirine exposure, with an area under the plasma concen-
tration–time curve during 0–12 h (AUC12h) that was 1.36
fold larger. The VRCZ plasma concentrations were slightly
raised, but no grade 3 or 4 adverse events were observed
during treatment. Park et al. [17] conducted a randomized
controlled trial to investigate the efﬁcacy of TDM of VRCZ
against invasive fungal infections. Although the proportion
of VRCZ discontinuation due to adverse events was sig-
niﬁcantly lower in the TDM group than in the non-TDM
group, routine TDM of VRCZ did not reduce the incidence
of drug-related adverse events because of the early occur-
rence of adverse events compared with the time needed for
optimizing VRCZ levels based on TDM.
Variability in the plasma concentration of VRCZ both
within and between individuals is high, especially in
pediatric patients. The in vitro metabolism of VRCZ by
liver microsomes mirrored the in vivo clearance differ-
ences in children versus adults, with VRCZ clearance being
approximately threefold higher in children than in adults
[18]. The VRCZ pharmacokinetics in children are highly
variable, particularly for oral formulations [19]. In an open-
label study of 12 immunocompromised children, wide
intra- and interindividual variations in the plasma VRCZ
levels were conﬁrmed [20]. Karlsson et al. [21] suggested
that children are especially at risk because VRCZ exhibits
markedly reduced oral bioavailability in children compared
with adults (44.6 vs. 96 %). Driscoll et al. [22] conducted a
study of children who were switched from intravenous to
oral treatment. In the study, large intersubject variability
was observed. In the steady state during oral treatment,
children had higher average exposure than adults. In ado-
lescents who were switched from intravenous to oral
treatment, large intersubject variability was observed;
however, VRCZ exposure in the majority of adolescents
was comparable to that in adults [23].
J Infect Chemother (2013) 19:381–392 383
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Several studies have demonstrated that the blood trough
level was associated with not only adverse events but also
treatment response. Smith et al. [8] retrospectively
researched patients treated with VRCZ for invasive
aspergillosis. Classiﬁcation and regression tree (CART)
analysis showed a relationship (P\ 0.025) between dis-
ease progression and drug concentration. Park et al. [17]
conﬁrmed the beneﬁcial effect of routine TDM in a ran-
domized, controlled trial. A clinical response was observed
in 81 % of patients in the TDM group compared to 57 % in
the non-TDM group, with a signiﬁcant difference. Among
allograft recipients receiving VRCZ for the prevention of
fungal infections, 6 candidiasis cases were seen among the
43 patients with VRCZ levels B2 lg/mL, whereas none
was seen among the 24 cases with higher levels
(P = 0.061) [6]. Triﬁlio et al. [24] conducted a retro-
spective study of VRCZ concentrations in recipients who
had undergone allogeneic HSCT and received VRCZ for
the prophylaxis of invasive fungal infection. Their data
suggested that VRCZ concentrations were unpredictable,
despite standard dosing, and the acceptability of a con-
centration on one occasion could not be extrapolated to
future concentrations in the same patient. Triﬁlio et al. [13]
measured the steady-state plasma trough VRCZ level and
found that VRCZ was undetectable in 15 % of the patients
in their series.
Pharmacokinetics–pharmacodynamics (PK–PD)
Executive summary
(a) The free AUC/MIC ratio is a PK–PD parameter
that appears to be associated with treatment efﬁcacy
(C1-III).
(b) The trough/MIC ratio can be used clinically in place
of the free AUC/MIC ratio (B-II).
(c) Because of high bioavailability, similar PK to intra-
venous administration was obtained in patients with
oral administration.
(d) Genotypic variation in the metabolizing enzyme
CYP2C19 is one of the major determinants of
toxicity. The frequency of poor metabolizers (PM),
i.e., individuals with defective or diminished meta-
bolic capacity, is higher among Asian patients.
Literature review
In an animal experiment using a neutropenic murine model
of disseminated Candida albicans infection, the treatment
efﬁcacy supported the use of the AUC/MIC ratio as a PK–
PD parameter that was predictive of efﬁcacy. Nonlinear
regression analysis also suggested that the AUC/MIC ratio
was strongly predictive of the treatment outcomes [25].
Andes [26] suggested that a free AUC/MIC value\25 was
associated with a half-maximal antifungal effect in murine
models of disseminated candidiasis.
Monte Carlo simulation can be used to assess the rela-
tionship between the VRCZ trough concentration/MIC
ratio and the clinical response. The probability of a clinical
response is near maximum when the trough/MIC ratio is
between 2 and 5. A previous study suggested that the
trough concentration is more clinically tractable [14].
Johnson and Kauffman [27] reported that the bioavail-
ability of the oral formulation was[90 % when adminis-
tered either 1 h before or 1 h after a meal, and similar PK
to intravenous administration was obtained in patients with
oral administration.
Mikus et al. [28] conducted a randomized controlled
trial to investigate interactions with VRCZ. The coadmin-
istration of a potent CYP3A4 inhibitor led to higher and
prolonged exposure to VRCZ that might have increased the
risk of the development of adverse drug reactions on a
short-term basis, particularly in CYP2C19 PM patients. In
gene analysis of a Japanese population, the frequency of
poor metabolizers was 18.8 % [29]. The genotype status of
CYP2C19 and/or the coadministration of drugs that mod-
ulate CYP2C19 or CYP3A4 activities might inﬂuence
VRCZ plasma levels. The inﬂuence of the genotype on
VRCZ exposure is confounded by drug–drug and drug–
disease interactions in the population; thus, no dose
adjustments based on genotype are recommended [30]. In
gene analysis in an Asian population, the frequency of the
CYP2C19 PM was similar to that in the Japanese popula-
tion [31]. In this study, subsequent studies have used a
combination of phenotyping and genotyping tests and have
conﬁrmed marked interethnic variation in the frequency of
the PM phenotype: there is a higher frequency of the trait in
Asian (12–23 %) than Caucasian (1–6 %) or Black African
(1–7.5 %) populations, and African-American and Arab
populations appear to be similar to Caucasians. Kimura
et al. [32] reported that the pharmacokinetics of VRCZ
were comparatively unstable and that the concentration
of VRCZ varied among individuals, regardless of the
CYP2C19 genotype.
Methods of TDM
Executive summary
(a) Blood samples for TDM should be obtained in the
steady state. Steady-state levels are achieved by
the 5th to 7th day of conventional administration
(B-II).
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(b) The trough level is recommended for the measure-
ment of TDM (B-II). Routine measurement of Cpeak
to calculate the AUC is not recommended (C2-III).
Literature review
Purkins et al. [33] suggested that steady-state levels were
achieved by the 5th to 6th day of multiple dosing, and
Lazarus et al. [34] suggested that steady-state levels were
achieved by the 4th to 7th day. The majority of these
pharmacokinetic estimates are based upon single trough
concentrations. It would be interesting to determine whe-
ther the use of additional monitoring time points to reﬂect
the AUC more accurately might further enhance the
strength of these concentration–outcome relationships.
Because of the high bioavailability ([90 %) of the oral
formulation [27], TDM can be performed using the same
timing in patients receiving the oral administration.
Target serum concentrations in TDM
Executive summary
(a) A target trough level C1–2 lg/mL is recommended in
terms of clinical efﬁcacy (B-II).
(b) In patients with a trough level[4–5 lg/mL, elevated
liver function test results potentially attributable to
VRCZ should be considered (B-II).
(c) As VRCZ exhibits nonlinear pharmacokinetics, the
blood concentration should be reevaluated in patients
revealing unexpectedly abnormal serum levels or
those with alteration of the dosage regimen (B-II).
(d) In patients receiving oral therapy, the TDM data
should be evaluated after conﬁrming the patient’s
adherence to the treatment and timing of ingestion
(C1-III).
Literature review
Ueda et al. [6] and Triﬁlio et al. [7] concluded that trough
VRCZ levels [2 lg/mL were associated with clinical
efﬁcacy. Smith et al. [8] found that favorable responses
were observed at concentrations [2.05 lg/mL. Miyakis
et al. [11] reported that successful outcomes were more
likely among patients with a median trough VRCZ con-
centration[2.2 lg/mL.
Pascual et al. [9] reported that a lack of response to
therapy was more frequent among patients with VRCZ
B1 lg/mL than in patients with VRCZ[1 lg/mL. Okuda
et al. [10] found a signiﬁcant difference (P\ 0.05) in
average trough blood concentrations between patients in
whom VRCZ was effective and those in whom VRCZ was
ineffective (8.21 ± 2.19 vs. 1.01 ± 0.86 lg/mL). Hamada
et al. [12] reported that for graded cutoff values within the
range of 1.0–3.0 lg/mL, VRCZ[1.0 lg/mL was used as
the VRCZ trough blood concentration (P\ 0.0001).
Because of the small number of PK–PD analyses con-
cerning clinical efﬁcacy in each study, target serum con-
centrations were not demonstrated according to the type of
infections and causative organisms.
Ueda et al. [6] reported that elevation of hepatic
enzymes was frequently observed when the VRCZ con-
centration was [6 lg/mL. Pascual et al. [9] found that
none of the patients in their series with levels B5.5 lg/mL
presented with neurological toxicity (P = 0.002). Okuda
et al. [10] found a signiﬁcant difference (P\ 0.05) in the
average trough blood concentrations between patients
presenting with adverse events and those with no adverse
events (7.64 ± 2.84 vs. 1.49 ± 1.79 lg/mL). Hagiwara
et al. [35] reported that the average VRCZ trough level of
patients with neurological adverse events was 3.2 lg/mL
and that the troughs of all the patients requiring discon-
tinuation because of hepatic disorder were [4.0 lg/mL.
Triﬁlio et al. [36] found that the VRCZ concentrations
were correlated with aspartate aminotransferase (AST)
(P = 0.0009) and alkaline phosphatase (ALP) (P = 0.03)
levels. As a result of logistic analysis, the probability of
hepatotoxicity at VRCZ trough concentrations of 2 and
4 lg/mL was 1.6 and 21.6 %, respectively [37]. Lutsar
et al. [38] showed a 7–17 % increase in the odds of an
abnormal alanine aminotransferase (ALT), AST, ALP, or
bilirubin level for every 1 lg/mL increase in the plasma
concentration of VRCZ. Denning et al. [39] reported that
ﬁve of six patients with VRCZ concentrations[10 lg/mL
developed adverse events requiring discontinuation from
the study. For neurological adverse effects, the increased
incidence for values [4.0 lg/mL was signiﬁcant when
examined in a meta-analysis (P = 0.02) [12]. However,
many neurological adverse events have been reported to be
transient and to disappear after the discontinuation of
VRCZ treatment; therefore, for safety purposes, caution
with regard to liver function is recommended when the
trough level exceeds 4–5 lg/mL.
VRCZ exhibited nonlinear pharmacokinetics in healthy
volunteers. This deviation from linear pharmacokinetics
was conﬁrmed by linearity ratios of[1 and decreasing kel
(elimination rate constant) values for multiple dosing, with
a consequent increase in the terminal phase t1/2 [33]. Pur-
kins et al. [40] found that VRCZ exhibited nonlinear
pharmacokinetics and that both the Cmax and the area under
the concentration–time curve within the dosage interval
(AUCs) increased disproportionately with the dose for both
intravenous (IV) and oral dosing. With oral administration,
patient compliance can be monitored using TDM [2, 41].
J Infect Chemother (2013) 19:381–392 385
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Initial administration regimen
Executive summary
Table 2 Initial administration regimen (B-II).
Literature review
VRCZ is available in both intravenous and oral formula-
tions. In adults, steady-state plasma levels after intravenous
infusion of 3–6 mg/kg twice daily range from 3 to 6 lg/mL
[42]. Steady-state concentrations are achieved only after
5–6 days but, if a loading dose is given, earlier steady-state
concentrations are obtained [39]; therefore, a loading dose
of 6 mg/kg every 12 h for 2 doses in patients with intra-
venous administration and 300 mg every 12 h for 2 doses
in oral administration is required.
Purkins et al. [43] conducted a randomized controlled
trial of 12 healthy volunteers. In the trial, the bioavailability
of twice-daily 200 mg VRCZ was reduced by approximately
22 %, as measured by AUCs, after multiple dosing taken
with food, compared with fasting. The results of this study
suggest that to maximize bioavailability, VRCZ should not
be administered immediately following a meal.
TDM in patients under particular clinical conditions
and pediatric considerations
Executive summary
For patients under the following clinical conditions and for
children, particular consideration is required because of
unstable pharmacokinetic parameters.
(a) Patients with impaired renal function: As PK of
VRCZ is not affected in subjects with renal impair-
ment, no adjustment in the dosage of the oral
formulation of VRCZ is necessary according to renal
function (B-II). Intravenous administration is not
recommended for patients with creatinine clearance
\30 ml/min because of the possible accumulation of
the intravenous vehicle sulfobutylether-beta-cyclo-
dextrin (SBECD) (B-II).
(b) Patients undergoing dialysis: It is recommended to
treat patients on dialysis therapy only with the oral
form of VRCZ, if feasible. In patients to whom
VRCZ is administered intravenously for any reason,
possible adverse events (altered consciousness level,
hemodynamic instability, skin reactions, deterioration
of liver function) caused by the accumulation of
SBECD should be monitored (C1-III).
(c) Patients with liver dysfunction: Dosage adjustments
are necessary for patients with liver dysfunction. The
standard loading dose should be used but the main-
tenance dosage should be halved in patients with
mild-to-moderate liver disease (Child–Pugh Class A
and B) (B-II). No studies have evaluated the safety of
VRCZ in patients with severe liver disease (Child–
Pugh Class C) (unresolved issue).
(d) Pediatric considerations
1. Although VRCZ is not approved for pediatric
patients, the dosage of 7 mg/kg every 12 h is
recommended in other countries (B-II). The
efﬁcacy and safety of higher doses, including a
loading dosage, are under investigation.
2. Relatively higher hepatic clearance of VRCZ
tends to cause a lower plasma concentration in
pediatric patients.
3. Lower bioavailability of oral VRCZ should be
considered in pediatric patients.
Literature review
(a) Patients with impaired renal function: Abel et al. [44]
reported that PK of VRCZ was unaffected in subjects
with any degree of renal impairment. As VRCZ has
limited aqueous solubility, the intravenous form
includes SBECD as a novel delivery system. In
healthy subjects, SBECD is rapidly eliminated with a
terminal half-life of 1.6 h. Clearance is linearly rela-
ted to creatinine clearance, and accumulation has
been described in subjects with moderate to severe
renal impairment (serum creatinine [2.5 mg/dl). In
patients with an estimated creatinine clearance of
30–50 ml/min, the mean Cmax and AUC of SBECD
increased by almost 50 % and fourfold, respectively,
compared to subjects with normal renal function [45].
Abel et al. [44] described that clearance of SBECD
was proportional to creatinine clearance. Although
two subjects had[30 % increase in serum creatinine
from baseline, these changes did not correlate with
SBECD trough levels. The majority of subjects with
Table 2 Initial administration regimen of voriconazole (VRCZ)
Loading dose (on day 1) Maintenance dose
IV
administration
6 mg/kg twice daily 3–4 mg/kg twice daily
Oral administration (between meals)
C40 kg 300 mg twice daily 150–200 mg twice
daily
\40 kg 150 mg twice daily 100 mg twice dailya
a The oral maintenance dose can be increased to 150 mg twice daily
in patients with inadequate response
386 J Infect Chemother (2013) 19:381–392
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moderate renal insufﬁciency were able to tolerate
7 days of intravenous VRCZ solubilized with
SBECD. Although adverse events regarding the
accumulation of SBECD have not been conﬁrmed so
far in a human study, target organs for toxic effects in
rodents were the kidney and liver with obstruction of
renal tubules and single-cell necrosis in the liver. Both
ﬁndings were a consequence of massive cytoplasmic
vacuolation [46].
(b) Patients undergoing dialysis: von Mach et al. [47]
showed the accumulation of SBECD in patients
treated with intravenous VRCZ and dialysis therapy;
however, there was no evidence of toxic effects
related to the concentrations of SBECD in these
patients. Higher SBECD exposure seemed to be
unavoidable in patients on dialysis if VRCZ was
administered intravenously. Although clinically rele-
vant toxicity with high SBECD concentrations
remains unknown [48], it is recommended to treat
patients on dialysis therapy only with the oral form of
VRCZ, if feasible. In the study of the VRCZ plasma
level in patients on dialysis,\1 % of the administered
VRCZ (200 mg dose) was recovered from the
dialysate 24 h after dosing in patients receiving renal
replacement therapy for end-stage renal disease by
peritoneal dialysis (PD). The PD clearance was
3.7 ml/min, and the VRCZ clearance was the lowest
for PD, followed by continuous venovenous hemo-
diaﬁltration and hemodialysis (20 and 121 ml/min,
respectively). The peritoneal clearance of VRCZ is
minimal; therefore, no dosage adjustment is required
for patients receiving PD therapy in whom the oral
form of VRCZ is used [49].
(c) Patients with hepatic dysfunction: In a multiple-dose
study, patients with Child–Pugh class [50] A and B
liver dysfunction who received a 50 % reduced
VRCZ maintenance dose achieved a mean AUC24
of 56.2 lg h/mL; in normal individuals who received
full-dose VRCZ, the AUC24 was 57.8 lg h/mL.
These data suggest that a 50 % reduction in the
maintenance dose of VRCZ is necessary for patients
with Child–Pugh Class A or B hepatic dysfunction to
avoid excessive VRCZ exposure [51]. VRCZ should
be administered without dosage adjustment to criti-
cally ill patients without liver cirrhosis undergoing
continuous venovenous hemodiaﬁltration; however,
according to the results in one patient, a reduction in
the maintenance dosing regimen for VRCZ might be
useful for patients with liver cirrhosis [52]. A VRCZ
case report with Child–Pugh Class C showed that
pharmacokinetic studies in patients with severe
hepatic impairment should be performed to establish
reliable dose recommendations for this group of
patients, who are at high risk of developing invasive
fungal infections. Although there is no clear evidence,
we also think that several TDM are required for
patients with severe hepatic impairment [53].
(d) Pediatrics considerations: In other countries, a dosage
of 7 mg/kg every 12 h has been used [19, 20, 22, 54,
55]. The pharmacokinetics of VRCZ is highly vari-
able in children, particularly for oral formulations
[18]. Because bioavailability and clearance in chil-
dren may differ from adults, a proposal for high-dose
administration, including the loading dosage, is
currently moving forward in Japan. Overall, a
weight-based oral dose may be more appropriate
than a ﬁxed dose for children [22]. Yanni et al. [18]
showed that VRCZ clearance is approximately three-
fold higher in children than in adults. In other reports,
VRCZ clearance was higher in children than in adults
[22, 56]. Walsh et al. [57] concluded that pediatric
patients have a higher capacity for eliminating VRCZ
than adults and that dosages of 4 mg/kg may be
required for children to achieve exposure consistent
with that occurring in adults after dosages of 3 mg/kg.
In a pharmacokinetic analysis of children, children
were especially at risk because VRCZ exhibits
markedly reduced oral bioavailability in children
compared with adults (44.6 vs. 96 %) [21].
Drug–drug interactions (Table 3)
Executive summary
(a) VRCZ has an inhibitory effect on CYP2C19, 2C9, and
3A4; therefore, careful attention is required when drugs
that are metabolized by these metabolizing enzymes
are administered concurrently with VRCZ (B-II).
(b) Serious consideration should be given to raising the
blood concentration of calcineurin inhibitors by two-
to threefold when VRCZ and calcineurin inhibitors
are coadministered (B-II).
Literature review
Mikus et al. [28] reported that the coadministration of a
potent CYP3A4 inhibitor leads to higher and prolonged
exposure to VRCZ, possibly increasing the risk of adverse
drug reactions. In a trial to study the interactions between
VRCZ and omeprazole, omeprazole was found to have no
clinically relevant effect on VRCZ exposure, suggesting that
no VRCZ dosage adjustment is necessary for patients in
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Table 3 Drug interactions
Drug CYP Mechanism
2C9 2C19 3A4
Contraindications
Rifampin s Because of induction of the CYP3A4 metabolism by rifampin, rifampin
decreased the steady-state Cmax and AUC of VRCZ
Rifabutin s Because of induction of the CYP3A4 metabolism by rifabutin, rifabutin
decreased the steady-state Cmax and AUC of VRCZ
Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of rifabutin
Efavirenz s s s Because of induction of the CYP2C19 and 2C9 metabolism by efavirenz,
efavirenz decreased the steady-state Cmax and AUC of VRCZ
Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of efavirenz
Ritonavir s s Because of induction of the CYP2C19 and 2C9 metabolism by ritonavir,
ritonavir decreased the steady-state Cmax and AUC of VRCZ
Carbamazepine s Because of induction of the CYP3A4 metabolism by carbamazepine,
carbamazepine decreased the steady-state Cmax and AUC of VRCZ
Barbital s Because of induction of the CYP3A4 metabolism by barbital, barbital
decreased the steady-state Cmax and AUC of VRCZ
Phenobarbital s Because of induction of the CYP3A4 metabolism by phenobarbital,
phenobarbital decreased the steady-state Cmax and AUC of VRCZ
Pimozide s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration and risk of cardiotoxicity (QT
prolongation, torsade de pointes, cardiac arrest) of pimozide
Quinidine s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration and risk of cardiotoxicity (QT
prolongation, torsade de pointes, cardiac arrest) of quinidine
Ergotamine s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration of ergot derivative and an increased risk of
ergotism (nausea, vomiting, vasospastic ischemia) of ergotamine
Triazolam s Because of inhibition of the CYP3A4 triazolam metabolism by VRCZ,
VRCZ increased plasma concentrations and potential of triazolam
Cautions
Phenytoin s s Because of induction of the CYP3A4 metabolism by phenytoin, phenytoin
decreased the steady-state Cmax and AUC of VRCZ
Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of phenytoin
Inhibitor of HIV protease (excluded
indinavir): saquinavir, amprenavir,
nelﬁnavir
s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration of HIV protease inhibitor
Because of inhibition of the CYP3A4 metabolism by HIV protease inhibitor,
HIV protease inhibitor increased plasma concentration of VRCZ
(n*) nucleoside reverse transcriptase
inhibitor (NNRTI): Delavirdine
s Because of inhibition of the CYP3A4 metabolism by NNRTI, NNRTI
increased plasma concentration of VRCZ
Because of induction of the CYP3A4 metabolism by NNRT, NNRT
decreased plasma concentration of VRCZ
Because of inhibition of the CYP3A4 metabolism by VRCZ VRCZ
increased plasma concentration of NNRTI
Cyclosporine s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of cyclosporine
Tacrolimus s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of tacrolimus
Warfarin s Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ
increased the prothrombin time of warfarin
Omeprazole s s Because of inhibition of the CYP2C19 and 3A4 metabolism by VRCZ,
VRCZ increased the steady-state Cmax and AUC of omeprazole
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whom omeprazole therapy is initiated [58]. Purkins et al.
[59] conducted two studies pertinent to the interactions
between VRCZ and phenytoin. Consequently, repeated dose
administration of phenytoin was shown to decrease the mean
steady-state Cmax and AUCs of VRCZ by approximately
50 and 70 %, respectively. The repeated dose administration
of 400 mg VRCZ twice daily increased the mean steady-
state Cmax and AUCs of phenytoin by approximately 70 and
80 %, respectively. Consequently, the plasma phenytoin
concentrations should be monitored.
Takashima et al. [60] conducted a retrospective study of
HSCT patients treated with tacrolimus. The oral adminis-
tration of VRCZ increased the blood concentration/dose
(C/D) ratio of tacrolimus by 2.7 fold, and the IV administra-
tion of VRCZ increased the C/D ratio by 2 fold. Considering
these results, the dosages of calcineurin inhibitors should be
reduced by 50–65 % when concomitantly administered with
VRCZ. Triﬁlio et al. [61] suggested that the dosage of ta-
crolimus may need to be reduced by 30–40 %. When VRCZ
and calcineurin inhibitors are coadministered, close and
periodic monitoring of the tacrolimus and cyclosporine con-
centrations is necessary in each patient to minimize dose-
related toxicity and to maximize efﬁcacy [62, 63].
Measurement of blood concentrations
Executive summary
High performance liquid chromatography (HPLC) is rec-
ommended to measure blood concentrations. No factors
affecting such measurements have been reported (B-III).
Table 3 continued
Drug CYP Mechanism
2C9 2C19 3A4
Midazolam s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration of midazolam
HMG-CoA reductase inhibitor s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration of HMG-CoA reductase inhibitor
Diazepam s s Because of inhibition of the CYP2C9 and 3A4 metabolism by VRCZ,
VRCZ increased the steady-state AUC and elimination half-life of
diazepam
Zolpidem s s Because of inhibition of the CYP2C9 and 3A4 metabolism by VRCZ,
VRCZ increased the steady-state Cmax and AUC of zolpidem
Sulfonylureas; tolbutamide s Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ
increased plasma concentration of sulfonylureas
Vinca alkaloids anticancer agents s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased plasma concentration of vinca alkaloidsVincristine
Vinblastine
Oxycodone s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of oxycodone
Fentanyl s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state AUC of fentanyl
Ibuprofen s Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ
increased steady-state Cmax and AUC of ibuprofen
Diclofenac s Because of inhibition of the CYP2C9 metabolism by VRCZ, VRCZ
increased steady-state Cmax and AUC of diclofenac
Oral contraceptive; norethindrone and
ethinyl estradiol
s s Because of inhibition of the CYP2C19 metabolism by norethindrone and
ethinyl estradiol, norethindrone and ethinyl estradiol increased steady-state
Cmax and AUC of VRCZ
Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased steady-state Cmax and AUC of norethindrone and ethinyl
estradiol
St. John’s wort s s Because of induction of the CYP3A4 and 2C19 metabolism by St. John’s
wort, St. John’s wort decreased the steady-state AUC of VRCZ
Overseas reference
Sirolimus s Because of inhibition of the CYP3A4 metabolism by VRCZ, VRCZ
increased the steady-state Cmax and AUC of sirolimus
Digoxin, cimetidine, ranitidine No change
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Literature review
To perform TDM, a validated analytical method must be
available to determine VRCZ plasma concentrations. The
various methods employed include HPLC with ultraviolet
or mass spectrometric and bioassays; however, for the
treatment of invasive antifungal infection, bioassays lack
sensitivity and speciﬁcity compared with HPLC, when
combination therapy is being used. Thus, HPLC may be the
most suitable assay for measuring VRCZ concentrations
[64–83].
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